Mocetinostat

Generic Name: Mocetinostat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₀N_₆O

CAS Number: 726169-73-9

Unique Ingredient Identifier: A6GWB8T96J

Background: Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Phase 1

Recruiting

Conditions: Rhabdomyosarcoma

Interventions: Drug: Vinorelbine
Drug: Mocetinostat

First Posted Date: 2020-03-06

Last Posted Date: 2024-06-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 38

Registration Number: NCT04299113

Locations: 🇺🇸
Rebecca Phelan, Los Angeles, California, United States

Pembrolizumab (immunotherapy Drug) in Combination with Guadecitabine and Mocetinostat (epigenetic Drugs) for Patients with Advanced Lung Cancer.

Phase 1

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Guadecitabine
Drug: Mocetinostat

First Posted Date: 2017-07-18

Last Posted Date: 2024-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT03220477

Locations: 🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Phase 1

Withdrawn

Conditions: Squamous Cell Carcinoma, Head And Neck
Resectable Squamous Cell Carcinoma of Oral Cavity
Squamous Cell Carcinoma Mouth

Interventions: Drug: Mocetinostat
Biological: Durvalumab

First Posted Date: 2016-12-15

Last Posted Date: 2017-12-29

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT02993991

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Glesatinib
Drug: Sitravatinib
Drug: Mocetinostat
Drug: Nivolumab

First Posted Date: 2016-11-04

Last Posted Date: 2024-04-22

Lead Sponsor: Mirati Therapeutics Inc.

Target Recruit Count: 161

Registration Number: NCT02954991

Locations: 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸
USOR - Texas Oncology - Denison Cancer Center, Denison, Texas, United States
🇺🇸
Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States

and more 22 locations

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Phase 2

Completed

Conditions: Metastatic Leiomyosarcoma

Interventions: Drug: Mocetinostat
Drug: Gemcitabine

First Posted Date: 2014-11-27

Last Posted Date: 2019-01-29

Lead Sponsor: Sarcoma Alliance for Research through Collaboration

Target Recruit Count: 20

Registration Number: NCT02303262

Locations: 🇺🇸
Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 2 locations

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Phase 1

Terminated

Conditions: Lymphoma
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Relapsed and Refractory

Interventions: Drug: Mocetinostat

First Posted Date: 2014-11-04

Last Posted Date: 2024-03-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT02282358

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Phase 2

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Mocetinostat

First Posted Date: 2014-09-10

Last Posted Date: 2017-09-01

Lead Sponsor: Mirati Therapeutics Inc.

Target Recruit Count: 17

Registration Number: NCT02236195

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 11 locations

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Phase 1

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Mocetinostat
Drug: Azacitidine

First Posted Date: 2013-12-23

Last Posted Date: 2017-09-14

Lead Sponsor: Mirati Therapeutics Inc.

Target Recruit Count: 18

Registration Number: NCT02018926

Locations: 🇺🇸
Georegetown University, Washington, D.C., District of Columbia, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
St. Francis Hospital, Greenville, South Carolina, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy